You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 8, 2025

New Draft Regulatory Framework for Food Product Declaration and Registration in Vietnam

In response to persistent challenges in food safety management and recent high-profile incidents involving counterfeit supplemented foods, infant formula, and health supplements, the Ministry of Health of Vietnam is initiating comprehensive regulatory reforms. These reforms include proposed amendments to the Law on Food Safety and its implementing Decree No. 15/2018/ND-CP (Decree 15), introducing significant changes to the registration procedures for food products, especially supplemented food products and health supplements.

While awaiting public consultation and approval of the amended Law on Food Safety, the Ministry of Health is developing an interim mechanism, which includes a draft decree to replace Decree 15 and a draft resolution to address urgent issues until the amended law becomes effective, expected in July 2026.

To align with the new Law on Quality of Products and Goods, the draft resolution stipulates that the declaration and registration of food products will follow the following procedures:

  • Declaration of applied standards for food products, which is currently known as the “self-declaration” procedure, applies to processed packaged foods, food additives, food processing aids, containers or utensils that come into direct contact with food, packaging materials in direct contact with food, and micronutrients.
  • Granting of circulation numbers, which is the current “registration of product declaration” procedure, applies to specific categories of food including health supplements, medical nutrition foods, special dietary foods, nutritional products for children up to 36 months, and, especially, supplemented foods, which are currently subject to self-declaration but will be shifted to this registration procedure.

In addition, the following new procedure is introduced in the draft decree:

  • Registration of declaration of conformity, which applies to the same product category as in “declaration of applied standards” above, but is for products that are already subject to technical regulations covering both safety indicators and quality indicators.

Changes to the Food Product Declaration and Registration Procedures

Details of the procedures for declaration of applied standards and granting of circulation numbers are stipulated in the draft resolution, while details of the procedure for registration of declaration of conformity are stipulated in the draft decree. These procedures will see some key changes compared to the current regulations, as highlighted below:

  • Letter of authorization: A letter of authorization (LOA) from the manufacturer or product owner to the entity conducting the declaration of applied standard or registration is a new requirement applicable to both procedures. Information that must be included in the LOA is detailed in the draft resolution.
  • Quality criteria: It is newly required to test quality criteria in a Certificate of Analysis (COA), in addition to safety criteria, for both procedures. The COA will need to follow the format set out in the draft resolution.
  • Declaration of conformity with internal standards: In addition to the declaration of compliance with food safety requirements, both product declaration and registration procedures have a new requirement that the declaring or registering entity must confirm that the product complies with its internal standards. This conformity is substantiated by submitting the in-house specification along with a dossier detailing the development of the specification.
  • Timeline for declaration of applied standards: The draft resolution introduces a defined principal evaluation timeline of 21 days from the date of submission—an element not specified under current regulations. It also clarifies that entities may begin manufacturing and trading declared products once the declaration, including the entity name and product name, is published on the authority’s official website.
  • Required documents: The required documents applicable to products subject to the registration of product declaration procedure are much more stringent than in current practice. The registration dossier will cover two parts: (i) administrative and (ii) technical. More technical documents will be required for the technical part, such as a manufacturer’s certificate (GMP, HACCP, etc.), report on product research and development process, documentation on quality and safety standards, documentation of manufacturing process, long-term stability report, and other technical explanation (if necessary).
  • Timeline for registration of product declaration: The estimated principal approval timeline is specifically set as 90 days from the date of submission. Compared to the current regulation, the timeline for submitting a supplemental dossier will be reduced from 90 working days to 60 working days from the date of receiving an official notice of deficiency. Notably, instead of an unlimited number of revisions, the draft resolution only permits a one-time revision.
  • Exclusion of certain products from the registration of product declaration procedure: Certain food additives—including blended food additives with new functions, those not on the Ministry of Health’s permitted list, or those used for incorrect purposes—are no longer subject to the registration of product declaration procedure under the draft resolution. Neither the draft resolution nor the draft decree specify how these products should be registered, suggesting that future regulations on food additive management may address this gap.

Suspension of Product Declaration Registration

The draft resolution introduces a new provision allowing competent authorities to temporarily suspend the receipt and processing of product declaration dossiers from entities who have violated food safety regulations. Processing will resume once the violations are fully remedied and a compliance report is submitted.

Transitional Provision

Under the draft decree, for food products that are registered or self-declared before the effective date of the decree, product owners must complete the procedures for re-registering or re-declaring product standards in accordance with the draft resolution (after it is enacted), within the following timeframes:

  • 18 months from the effective date of the decree for products that already have a Certificate of Receipt for Product Declaration.
  • 6 months from the effective date of the decree for products that are self-declared.

After these deadlines, any previous product declaration documents or certificates will no longer be valid for production or importation. However, products with a certificate that were produced within 18 months of the decree’s effective date and products that were self-declared and produced within 6 months of the decree’s effective date may continue to be circulated until their expiration date, and the product owner remains fully responsible for those products.

The draft decree does not specify a transitional period for the supplemented food products that will be shifted from the self-declaration procedure to the registration of product declaration procedure.

The draft resolution and draft decree will be discussed and approved under the fast-track procedure. However, no expected effective date has been provided. It remains possible that further revisions to the draft decree may be introduced.

Impact for Businesses and Next Steps

Businesses will be required to prepare additional documentation for declaration and registration processes to comply with the new regulations once they are enacted. Stricter documentation will be required for products subject to registration of declaration procedure, especially for supplemented foods, which are shifted from self-declaration procedure to registration of product declaration procedure.

Businesses should review their product portfolios to determine applicable registration pathways, develop plans to update the declaration and registration dossiers, and monitor for further amendment, official issuance, and implementation guidance.

RELATED INSIGHTS​ 

March 7, 2025
On November 22, 2024, the Ministry of Health (MOH) in Laos issued Decision No. 3730/MOH, which regulates the management, processing, production, and use of biopharmaceutical products, genes, and stem cells. This decision came into force on January 18, 2025, 45 days after its publication in the Lao Official Gazette on December 4, 2024. This decision signifies Laos’ recognition and acceptance of biopharmaceutical products, genes, and stem cells for use in medical treatments and the beauty industry, and it aligns with the ongoing development of biomedical sciences in the country. Definitions The MOH’s decision defines biopharmaceuticals, gene therapy, and stem cells as follows: “Biopharmaceutical products” refers to a type of biological or drug product that is produced or synthesized from natural substances, objects, or chemicals. This group of products includes blood, blood components, allergens, cells or cellular components, gene therapies, tissues, protein-based medicines, drugs derived from living cells, and biologics, which can be produced from sugars, proteins, amino acids, or substances with complex characteristics derived from organic sources such as human, animal, and plant parts; yeast; and microorganisms. These products exclude vaccines and biosimilar products, which will be specified under separate regulations. “Gene therapy” refers to a treatment approach that applies the principle of arranging amino acids (which could involve DNA or RNA sent to the patient’s cells in the form of a drug with the purpose of treating a certain disease). “Stem cells” are defined in the decision as cells or immature cells that can be sourced from various organs in the They are characterized by being undifferentiated, having the potential for differentiation, and being self-renewing. Stem Cell Production The decision outlines comprehensive provisions for managing and using raw materials in stem cell production. Key points include: Production location standards: Ensuring facilities meet specific standards of the MOH. Personnel
December 13, 2024
Experts from Tilleke & Gibbins have provided updates for the latest edition of The Pharma Legal Handbook: Vietnam, published by Pharma Boardroom. This comprehensive guide to the legal framework regulating the healthcare and life sciences industries in Vietnam was authored by by the Hanoi-based team of Hien Thi Thu Vu, head of regulatory affairs for Vietnam, and Mai Thi Le, regulatory affairs consultant, the handbook is a must-read for healthcare and life sciences companies that are interested in the Vietnam market. The guide includes eight sections on various important aspects of local regulations: Regulatory, Pricing, and Reimbursement Overview Preclinical & Clinical Trial Requirements Marketing, Manufacturing, Packaging & Labeling, and Advertising Traditional Medicines and Over-the-Counter Products Product Liability Patents and Trademarks Regulatory Reforms Orphan Drugs and Rare Diseases Tilleke & Gibbins has also authored The Pharma Legal Handbook: Thailand, which was updated at the same time as the Vietnam guide. The Pharma Legal Handbook: Vietnam, like all of the country guides from Pharma Boardroom, is available for purchase on the Pharma Boardroom website.
December 13, 2024
Attorneys from Tilleke & Gibbins in Bangkok have provided updates for the latest edition of The Pharma Legal Handbook: Thailand, published by Pharma Boardroom. This comprehensive guide to the legal framework regulating the healthcare and life sciences industries in Thailand was authored by Alan Adcock, partner and director, intellectual property, and head of the firm’s life sciences practice; Dr. Atthachai Homhuan, manager of regulatory affairs; and San Chaithiraphant, senior associate. The handbook is a must-read for healthcare and life sciences companies that are interested in exploring expansion into the Thai market.
December 12, 2024
On November 21, 2024, the National Assembly of Vietnam adopted a law amending and supplementing the 2016 Law on Pharmacy (“Amended Law on Pharmacy”). The Amended Law on Pharmacy simplifies some procedures for the pharmaceutical field, and will take effect on July 1, 2025, except for regulations on drug registration and rights and responsibilities of certain types of pharmaceutical business. Some outstanding points in the Amended Law on Pharmacy are presented below. E-commerce Distribution The Amended Law on Pharmacy allows trading in pharmaceutical products by the e-commerce channel, including e-commerce trading floors, e-commerce sales applications, and e-commerce sales websites with online ordering functions. Accordingly, e-commerce retail of non-prescription drugs is permitted if the drugs are neither specially controlled drugs nor drugs included in the list of drugs restricted for retail sale, and e-commerce wholesale of drugs and drug materials is permitted, as long as they are not specially controlled drugs. New Rights for Import FIEs The amendment provides some additional rights to foreign-invested enterprises (“FIEs”) that import drugs, including the rights to: Repurchase drugs and drug materials manufactured through the technology transfer of the FIE itself in Vietnam, and sell such products to wholesalers; Import drug materials to supply to drug manufacturers in Vietnam that are hired by or receive technology transfer from the FIE itself under a processing contract or technology transfer contract; Deliver and transport drugs and drug materials the FIE has imported, outsourced for processing, or transferred technology for in Vietnam, from the FIE’s warehouse to its wholesalers; Deliver and transport drugs used in aid, sponsorship, humanitarian, and disease prevention and control programs to medical facilities receiving funding; and Transport drug materials imported by the FIE from its warehouse to drug manufacturers that are hired by or receive technology transfer from the FIE itself under a